US Patent Issued to Beijing Innocare Pharma Tech on Aug. 25 for "Heterocyclic compound as BCL-2 inhibitor" (Chinese Inventors)

ALEXANDRIA, Va., Aug. 25 -- United States Patent no. 12,715,870, issued on Aug. 25, was assigned to Beijing Innocare Pharma Tech Co. Ltd. (Beijing).

"Heterocyclic compound as BCL-2 inhibitor" was invented by Norman Xianglong Kong (Nanjing, China), Chao Zhou (Nanjing, China) and Zhixiang Zheng (Nanjing, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to a compound, a pharmaceutical composition containing thereof, preparation methods therefor, and use thereof as BCL-2 inhibitors. The compound is a compound represented by formula (I), or an isomer, prodrug, solvate, stable isotopic derivative or pharmaceutically acceptable salt thereof. The invention also relates to use of the...